摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)acetamide | 1264718-62-8

中文名称
——
中文别名
——
英文名称
2-[3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)acetamide
英文别名
2-(3,5-bis((E)-4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-N-(prop-2-yn-1-yl)acetamide;2-[3,5-bis[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]pyrazol-1-yl]-N-prop-2-ynylacetamide
2-[3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)acetamide化学式
CAS
1264718-62-8
化学式
C26H25N3O5
mdl
——
分子量
459.502
InChiKey
URTVZMMRDHIPGL-NXZHAISVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    727.4±60.0 °C(Predicted)
  • 密度:
    1.18±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    34
  • 可旋转键数:
    9
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    106
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)acetamide 在 sodium hydroxide 、 lithium diisopropyl amide 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 1.0h, 生成 2-[3,5-bis[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]pyrazol-1-yl]-2-deuterio-N-(3-deuterioprop-2-ynyl)acetamide
    参考文献:
    名称:
    Synthesis of labeled curcumin derivatives as tools for in vitro blood brain barrier trafficking studies
    摘要:
    成功地将药物输送到大脑对于治疗包括阿尔茨海默病在内的多种神经系统疾病至关重要。我们合成了一种稳定的三价吡唑姜黄素衍生物,它能与 Aβ 肽相互作用,可在体外血脑屏障模型中进行跟踪研究。
    DOI:
    10.1002/jlcr.1907
  • 作为产物:
    描述:
    姜黄素1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺三氟乙酸 、 potassium hydroxide 作用下, 以 甲醇N,N-二甲基甲酰胺甲苯 为溶剂, 反应 2.75h, 生成 2-[3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)acetamide
    参考文献:
    名称:
    Synthesis of labeled curcumin derivatives as tools for in vitro blood brain barrier trafficking studies
    摘要:
    成功地将药物输送到大脑对于治疗包括阿尔茨海默病在内的多种神经系统疾病至关重要。我们合成了一种稳定的三价吡唑姜黄素衍生物,它能与 Aβ 肽相互作用,可在体外血脑屏障模型中进行跟踪研究。
    DOI:
    10.1002/jlcr.1907
点击查看最新优质反应信息

文献信息

  • Curcumin derivatives with improved physicochemical properties and nanoliposomes surface-decorated with the derivatives with very high affinity for amyloid-beta1-42 peptide
    申请人:Niaraki, Anna
    公开号:EP2436673A1
    公开(公告)日:2012-04-04
    Amyloid β (Aβ) aggregates are considered as possible targets for therapy and/or diagnosis of Alzheimer disease (AD). It has been previously shown that curcumin targets Aβ plaques and interferes with their formation, suggesting a potential role for prevention or treatment of AD. In the present invention, curcumin-derivatives with improved physicochemical properties were synthesized and a "click chemistry" as well as a conventional liposome preparation method, were used to generate nanoliposomes decorated with the curcumin derivatives. These derivatives were designed to maintain the planar structure required for interaction with Aβ, as directly confirmed by Surface Plasmon Resonance experiments. Surface Plasmon Resonance experiments, measuring the binding of flowing liposomes to immobilized Aβ1-42, indicated that the liposomes exposing curcumin derivatives have extremely high affinity for Aβ1-42 fibrils (1-5 nM), likely because of the occurrence of multivalent interactions. The present invention describes the synthesis of the curcumin derivatives and the preparation and characterization of new nanoliposomes with a very high affinity for Aβ1-42 fibrils, to be exploited as vectors for the targeted delivery of new diagnostic and therapeutic molecules for AD.
    淀粉样蛋白β(Aβ)聚集物被认为是治疗和/或诊断阿尔茨海默病(AD)的可能靶点。先前已经显示姜黄素靶向Aβ斑块并干扰其形成,暗示了其在预防或治疗AD中的潜在作用。在本发明中,合成了具有改进的物理化学性质的姜黄素生物,并使用“点击化学”以及传统的脂质体制备方法,生成了装饰有姜黄素生物的纳米脂质体。这些衍生物被设计为保持与Aβ相互作用所需的平面结构,直接通过表面等离子共振实验证实。通过测量流动脂质体与固定的Aβ1-42的结合,表面等离子共振实验证明,暴露姜黄素生物的脂质体对Aβ1-42纤维具有极高的亲和力(1-5 nM),可能是由于多价相互作用的发生。本发明描述了姜黄素生物的合成以及具有极高亲和力的新型纳米脂质体的制备和表征,可作为用于靶向传递新的AD诊断和治疗分子的载体。
  • [EN] MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM<br/>[FR] GEL INJECTABLE THERMOSENSIBLE À BASE DE PRO-MÉDICAMENT MACROMOLÉCULAIRE EN TANT QUE NOUVELLE PLATEFORME D'ADMINISTRATION DE MÉDICAMENT
    申请人:UNIV NEBRASKA
    公开号:WO2020087057A1
    公开(公告)日:2020-04-30
    This application discloses prodrug-based thermosensitive gel ("ProGel") comprised of conjugates of dmg molecules with water-soluble polymeric carriers, which are capable of controlled release of the dmg molecules into the tissue of a subject. Use of the ProGel-Drug conjugates for treatment of various diseases or disorders and methods of preparing them are also disclosed.
    这种应用披露了基于前药的热敏凝胶(“ProGel”),由dmg分子与溶性聚合物载体的共轭物组成,能够将dmg分子控制释放到受试者的组织中。还披露了将ProGel-药物共轭物用于治疗各种疾病或紊乱的方法以及制备它们的方法。
  • Synthesis and evaluation of a 18F-curcumin derivate for β-amyloid plaque imaging
    作者:Johanna Rokka、Anniina Snellman、Cristiano Zona、Barbara La Ferla、Francesco Nicotra、Mario Salmona、Gianluigi Forloni、Merja Haaparanta-Solin、Juha O. Rinne、Olof Solin
    DOI:10.1016/j.bmc.2014.03.010
    日期:2014.5
    In vitro studies of [18F]4 with the transgenic APP23 mouse revealed high β-amyloid plaque binding. In vivo and ex vivo studies demonstrated that [18F]4 has fast clearance from the blood, moderate metabolism but low blood–brain barrier (BBB) penetration. Conclusions [18F]4 was synthesized in high yield and excellent quality. In vitro studies, metabolite profile, and fast clearance from the blood indicated
    介绍 姜黄素是一种神经保护性化合物,可抑制淀粉样蛋白低聚物和原纤维的形成,并与阿尔茨海默病(AD)中的β-淀粉样蛋白斑块结合。我们旨在合成18 F标记的姜黄素生物([ 18 F] 4),并表征其在AD转基因APP23小鼠模型中的正电子发射断层扫描(PET)示踪剂与β-淀粉样蛋白斑块的结合特性。 方法 我们利用亲核的18 F化和点击化学,轻松地一锅合成[ 18 F] 4。使用针对PIB的异源竞争性结合,体外研究了转基因APP23小鼠脑冷冻切片中[ 18 F] 4与β-淀粉样蛋白斑的结合。[ 18 F] 4在啮齿类动物体内和体内的摄取研究使用转基因APP23和野生型对照小鼠的PET /计算机断层扫描技术进行。 结果 [ 18 F] 4的放射化学产率为21±11%,比活度超过1 TBq /μmol,合成结束时放射化学纯度超过99.3%。用转基因APP23小鼠对[ 18 F] 4进行的体外研究
  • MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM
    申请人:Board of Regents of the University of Nebraska
    公开号:US20220008543A1
    公开(公告)日:2022-01-13
    This application discloses prodrug-based thermosensitive gel (“ProGel”) comprised of conjugates of dmg molecules with water-soluble polymeric carriers, which are capable of controlled release of the dmg molecules into the tissue of a subject. Use of the ProGel-Drug conjugates for treatment of various diseases or disorders and methods of preparing them are also disclosed.
查看更多